

CURRICULUM VITAE

NAME: DAVIDE BOLIGNANO



DOB 31st October 1980

POB Reggio Calabria, Italy.

Address

National Council of Research Institute of Biomedicine and Molecular Immunology "A.Monroy" Based in Reggio Calabria; Via Vallone Petrarra snc, 89124 Reggio Calabria, Italy

E-mail davide.bolignano@gmail.com

CURRENT POSITION

Clinical researcher of the Italian National Research Council (CNR) at the Institute of Biomedicine and Molecular Immunology (IBIM) in Reggio Calabria, Italy.

EDUCATION AND PROFESSIONAL EXPERIENCE

Davide Bolignano is born on 31 October 1980 in Reggio Calabria, Italy. He graduated in Medicine from the University of Messina (Italy) in 2004 and obtained the post-graduate specialization in nephrology in 2009, both cum laude.

He currently works as clinical researcher of the Italian National Research Council (CNR) at the Institute of Biomedicine and Molecular Immunology (IBIM) in Reggio Calabria, Italy. Dr. Bolignano has participated in several national and international scientific congresses and courses focusing on epidemiology, biostatistics, physiology and pathophysiology of kidney diseases. In 2012 he has joined the Cochrane Renal Group (Sydney, Australia) as an honorary research fellow, learning skills in systematic reviews, meta-analysis, literature searching and the guidelines development process. Up to now (July 2012), Dr. Bolignano is co-author of 2 monographies, 66 scientific papers (29 as first author; h-index 13, g-index 27) published on national and international peer-review journals and several poster presentations, free communications and invited lectures at national and international congresses on nephrology, metabolism, cardiovascular and laboratory medicine. His main fields of research are: the epidemiology and pathophysiology of chronic and acute kidney diseases, renal biomarkers, cardiovascular risk, vasopressin system, medullar and systemic effects of erythropoietin and stem cells in uremia. In 2008, he has been awarded as "Best young researcher" by the University of Messina for the outstanding scientific production and by ERA-EDTA (in 2008, 2010 and 2011) and the Italian Society of Nephrology (in 2010) for scientific abstracts presented during annual congresses. Dr. Bolignano is reviewer for many national and international journals of clinical and experimental nephrology, hypertension,

metabolism, cardiovascular and laboratory medicine. He is member of the Italian Society of Nephrology and the European Renal Association (ERA-EDTA) and is currently involved in the diabetes guidelines project of the European Renal Best Practice group (ERBP). In 2011, Dr. Bolignano has been recruited by the Superior Health Institute (ISS; the leading technical-scientific body of the Italian National Health Service) to update the guideline on "Identification, prevention and management of Chronic Kidney Disease in adults" as methodologist reviewer of literature.

ARTICLES ON NATIONAL AND INTERNATIONAL PEER-REVIEWED JOURNALS

1. Bolignano D. Serum creatinine and the search for new biomarkers of acute kidney injury (AKI): the story continues. *Clin Chem Lab Med*. 2012, In press.
2. Bolignano D. TNF- α receptors (TNFRs): the biomarkers of progressive diabetic nephropathy we were waiting for? *G Ital Nefrol*. 2012 May;29(3):262.
3. Bolignano D, Zoccali C. Glitazones in chronic kidney disease: potential and concerns. *Nutr Metab Cardiovasc Dis*. 2012 Mar;22(3):167-75
4. Donato V, Noto A, Lacquaniti A, Bolignano D, Versaci A, David A, Spinelli F, Buemi M. Levels of neutrophil gelatinase-associated lipocalin in 2 patients with crush syndrome after a mudslide. *Am J Crit Care*. 2011 Sep;20(5):405-9.
5. Curatola G, Bolignano D, Rastelli S, Caridi G, Tripepi R, Tripepi G, Politi R, Catalano F, Delfino D, Ciccarelli M, Mallamaci F, Zoccali C. Ultrafiltration intensification in hemodialysis patients improves hypertension but increases AV fistula complications and cardiovascular events. *J Nephrol*. 2011 Jul-Aug;24(4):465-73.
6. Buemi M, Campo S, Donato V, Cernaro V, Lacquaniti A, Buemi A, Crasci E, Giorgianni G, Lucisano S, Bolignano D. A new therapy for kidney injury: regeneration. *Eur Rev Med Pharmacol Sci*. 2011 Feb;15(2):111-21.
7. Coppolino G, Bolignano D, De Paola L, Giulino C, Mannella A, Riccio M, Mascaro MA, Lombardi G, Fuiano G, Lombardi L, Buemi M. Parathyroid Hormone and Mobilization of Circulating Bone Marrow-Derived Cells in Uremic Patients. *J Investig Med*. 2011 Mar 3
8. Cernaro V, Bolignano D, Donato V, Lacquaniti A, Buemi A, Crasci E, Lucisano S, Buemi M. NGAL is a Precocious Marker of Therapeutic Response. *Curr Pharm Des*. 2011 Mar 7.
9. Lacquaniti A, Bolignano D, Donato V, Chirico V, Romeo A, Loddo S, Buemi M. Obestatin: A New Element for Mineral Metabolism and Inflammation in Patients on Hemodialysis. *Kidney Blood Press Res*. 2011 Jan 29;34(2):104-110.
10. Bolignano D. AVP: a new target in the treatment of chronic kidney disease? *G Ital Nefrol*. 2010 November-December;27(6):561
11. De Paola L, Coppolino G, Bolignano D, Buemi M, Lombardi L. PTH variability parameters for identifying high turn-over osteodystrophy disease in hemodialysis patients : an observational retrospective cohort study. *Ther Apher Dial* 2010. Dec;14(6):566-71
12. Bolignano D, Zoccali C. Vasopressin beyond water: implications for renal diseases. *Curr Opin Nephrol Hypertens*. 2010. Sep;19(5):499-504.
13. Buemi M, Donato V, Bolignano D. Erythropoietin: pleiotropic actions.

Recenti Prog Med. 2010 Jun;101(6):253-67.

14. Barresi V, Ieni A, Bolignano D, Magno C, Buemi M, Barresi G. Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: Correlation with histotype and histological grade. *Oncol Rep.* 2010 Aug;24(2):305-310.

15. Bolignano D, Coppolino G, Donato V, Lacquaniti A, Bono C, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL): a new missing piece of the anemia puzzle? *Med Sci Monit.* 2010 Jun;16(6):RA131-5.

16. Coppolino G, Lucisano G, Bolignano D, Buemi M. Acute cardiovascular complications of hemodialysis. *Minerva Urol Nefrol.* 2010 Mar;62(167-80):67-80.

17. Bolignano D, Coppolino G, Lacquaniti A, Buemi M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. *Eur J Clin Invest* 2010 Mar;40(3):273-6.

18. Bolignano D, Coppolino G, Romeo A, Lacquaniti A, Buemi A. Neutrophil Gelatinase-Associated Lipocalin (NGAL) Levels in Chronic Hemodialysis Patients. *Nephrology (Carlton).* 2010 Feb;15(1):23-6.

19. Lacquaniti A, Bolignano D, Donato V, Bono C, Fazio MR, Buemi M. Alterations of Lipid Metabolism in Chronic Nephropathies: Mechanisms, Diagnosis and Treatment. *Kidney Blood Pres Res.* 2010 Mar 27;33(2):100-110.

20. Buemi M, Costa C, Floccari F, Coppolino G, Campo S, Bolignano D, Sturiale A, Lacquaniti A, Buemi A, Loddo S, Teti D. Genomic damage in Endothelial Progenitor Cells from uremic patients in Hemodialysis. *J Nephrol* 2010 May-Jun;23(3):328-34.

21. Bolignano D. Neutrophil Gelatinase-Associated Lipocalin (NGAL): a biomarker beyond the confines of nephrology. *G Ital Nefrol* 2010. January-February;27(1):6.

22. Bolignano D, Della Torre A, Lacquaniti A, Costantino G, Fries W, Buemi M. Neutrophil Gelatinase Associated Lipocalin (NGAL) levels in patients with Crohn's Disease undergoing treatment with infliximab. *J Investig Med* 2010 Mar;58(3):569-71.

23. Arena A, Stassi G, Iannello D, Gazzara D, Calapai M, Bisignano C, Bolignano D, Lacquaniti A, Buemi M. Both IL-1 β and TNF- α Regulate NGAL Expression in Polymorphonuclear Granulocytes of Chronic Hemodialysis Patients. *Mediators Inflamm.* 2010;2010:613937. Epub 2011 Mar 3.

24. D'anna R, Baviera G, Giordano D, Todarello G, Russo S, Recupero S, Bolignano D, Corrado F. Neutrophil gelatinase-associated lipocalin serum evaluation through normal pregnancy and in pregnancies complicated by preeclampsia. *Acta Obstet Gynecol Scand* 2010;89(2):275-8.

25. Buemi M, Fazio MR, Bolignano D, Coppolino G, Donato V, Lacquaniti A, Mondello S, Buemi A, Allegra A. Renal complications in onco-hematologic patients. *J Investig Med* 2009 Dec;57(8):892-901.

26. Bolignano D, Coppolino G, Lacquaniti A, Buemi M. Neutrophil gelatinase-associated lipocalin in the intensive care unit: time to look beyond a single, threshold-based measurement? *Crit Care Med.* 2009 Oct;37(10):2864.

27. Buemi M, Lacquaniti A, Bolignano D, Cernaro V, Campo S, Grasso G, Buemi A, Donato V, Sturiale A. Down with the erythropoietin. Long live the erythropoietin! *Curr Drug Targets.* 2009 Oct;10(10):1028-32.

28. Bolignano D, Coppolino G, Lombardi L, Buemi M. NGAL: A New Missing

Link between Inflammation and Uremic Anemia? *Ren Fail.* 2009;31(7):622-3.

29. Allegra A, Coppolino G, Bolignano D, Giacobbe MS, Alonci A, D'Angelo A, Bellomo G, Teti D, Loddo S, Musolino C, Buemi M. Endothelial progenitor cells: pathogenetic role and therapeutic perspectives. *J Nephrol.* 2009 Jul-Aug;22(4):463-75.

30. Buemi M, Lacquaniti A, Bolignano D, Maricchiolo G, Favalaro A, Buemi A, Grasso G, Donato V, Giorgianni G, Genovese L, Coppolino G, Sfacteria A. The erythropoietin and regenerative medicine: a lesson from fish. *Eur J Clin Invest.* 2009 Nov;39(11):993-9.

31. Coppolino G, Buemi A, Bolignano D, Lacquaniti A, La Spada M, Stilo F, De Caridi G, Benedetto F, Loddo S, Buemi M, Spinelli F. Perioperative Iloprost and Endothelial Progenitor Cells in Uremic Patients With Severe Limb Ischemia Undergoing Peripheral Revascularization. *J Surg Res.* 2009 Nov;157(1):e129-35.

32. Bolignano D, Coppolino G, Romeo A, De Paola L, Buemi A, Lacquaniti A, Nicocia G, Lombardi L, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) reflects iron status in haemodialysis patients. *Nephrol Dial Transplant.* 2009 Nov;24(11):3398-403.

33. Bolignano D, Donato V, Lacquaniti A, Fazio MR, Bono C, Coppolino G, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: A new protein enters the scene. *Cancer Lett.* 2010 Feb 1;288(1):10-6.

34. Buemi M, Lacquaniti A, Maricchiolo G, Bolignano D, Campo S, Cernaro V, Sturiale A, Grasso G, Buemi A, Allegra A, Donato V, Genovese L. Regenerative Medicine: does Erythropoietin have a role? *Curr Pharm Des.* 2009;15(17):2026-36.

35. Buemi M, Campo S, Bolignano D. Erythropoietin and cancer: an old risk. *Am J Kidney Dis.* 2009 Jun;53(6):1102.

36. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, Buemi M. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. *Kidney Blood Press Res.* 2009;32(2):91-8.

37. Lacquaniti A, Bolignano D, Campo S, Perrone C, Donato V, Fazio MR, Buemi A, Sturiale A, Buemi M. Malnutrition in the elderly patient on dialysis. *Ren Fail.* 2009;31(3):239-45.

38. Bolignano D, Medici MA, Coppolino G, Sciortino MT, Merlo FM, Campo S, Donato V, Venuti A, Sturiale A, Zaccaria D, Buemi A, Lacquaniti A, Buemi M. Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R). *Urol Oncol.* 2010 Nov-Dec;28(6):642-7.

39. Bolignano D, Basile G, Parisi P, Coppolino G, Nicocia G, Buemi M. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. *Rejuvenation Res.* 2009 Feb;12(1):7-14.

40. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. *Clin J Am Soc Nephrol.* 2009 Feb;4(2):337-44.

41. Buemi M, Coppolino G, Bolignano D, Sturiale A, Campo S, Buemi A, Crasci E, Romeo A. Arrhythmias and hemodialysis: role of potassium and new diagnostic tools. *Ren Fail.* 2009;31(1):75-80.

42. Bolignano D, Medici MA, Buemi M. Aquaretic-induced apoptosis: a cure or a curse? *Eur J Clin Invest.* 2008 Nov;38(11):874-5.

43. Bolignano D, Coppolino G, Aloisi C, Romeo A, Nicocia G, Buemi M. Effect of a single intravenous immunoglobulin infusion on neutrophil gelatinase-associated lipocalin levels in proteinuric patients with normal renal function. *J Investig Med*. 2008 Dec;56(8):997-1003.
44. Buemi M, Bolignano D, Barilla A, Nostro L, Crasci E, Campo S, Coppolino G, D'Anna R. Preeclampsia and cardiovascular risk: general characteristics, counseling and follow-up. *J Nephrol*. 2008 Sep-Oct;21(5):663-72.
45. Buemi M, Lacquaniti A, Bolignano D, Donato V, Fazio MR, Campo S, Coppolino G, Sturiale A. Dialysis and the elderly: an underestimated problem. *Kidney Blood Press Res*. 2008;31(5):330-6.
46. Bolignano D, Coppolino G, Lacquaniti A, Nicocia G, Buemi M. Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. *Kidney Blood Press Res*. 2008;31(4):274-9.
47. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. *Am J Kidney Dis*. 2008 Sep;52(3):595-605.
48. Coppolino G, Bolignano D, Campo S, Loddo S, Teti D, Buemi M. Circulating progenitor cells after cold pressor test in hypertensive and uremic patients. *Hypertens Res*. 2008 Apr;31(4):717-24.
49. Bolignano D, Lacquaniti A, Coppolino G, Campo S, Arena A, Buemi M. Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. *Kidney Blood Press Res*. 2008;31(4):255-8.
- 4
50. Coppolino G, Campo S, Crasci E, Aloisi C, Giacobbe MS, Bolignano D, Sturiale A, Buemi M. Neurobiological model and quality of life in discovering personality of the uremic patient. *J Nephrol*. 2008 Mar-Apr;21 Suppl 13:S139-45.
51. Coppolino G, Campo S, Bolignano D, Sturiale A, Giacobbe MS, Loddo S, Buemi M. Effect of immunoglobulin treatment on endothelial progenitor cells in systemic lupus erythematosus. *Ann Rheum Dis*. 2008 Jul;67(7):1047-8.
52. Bolignano D, Coppolino G, Crasci E, Campo S, Aloisi C, Buemi M. Pregnancy in uremic patients: an eventful journey. *J Obstet Gynaecol Res*. 2008 Apr;34(2):137-43.
53. Floccari F, Cosentini V, Giacobbe M, Coppolino G, Campo S, Bolignano D, Tripodo D, Nostro L, Buemi M. A case-by-case protocol of membranous nephropathy treatment with endovenous infusion of high doses of human immunoglobulins. *Nephron Clin Pract*. 2008;108(2):c113-20.
54. Coppolino G, Basile G, Bolignano D, Mauro VN, Buemi M. Circulating endothelial progenitor cell mobilization in centenarians: a powerful source for extended renal life. *J Am Geriatr Soc*. 2007 Oct;55(10):1693-4.
55. Bolignano D, Coppolino G, Campo S, Aloisi C, Nicocia G, Frisina N, Buemi M. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. *Nephrol Dial Transplant*. 2008 Jan;23(1):414-6.
56. Buemi M, Bolignano D, Coppolino G, Sturiale A, Campo S, Crasci E, Aloisi C, Frisina N. La terapia con gli antagonisti della vasopressina: gli acquaretici. [Therapy with vasopressin receptor antagonists: the aquaretics]. *G Ital Nefrol*. 2007 Sep-Oct;24(5):371-80.

57. Coppolino G, Bolignano D, Parisi S, Aloisi E, Romeo A, Quartarone A, Buemi M. Experimental therapies in renal replacement: the effect of two different potassium acetate-free biofiltration protocols on striated muscle fibers. *Ther Apher Dial.* 2007 Oct;11(5):375-81.
58. Buemi M, Bolignano D, Coppolino G, Di Pasquale G, Cosentini V, Campo S, Barilla A, Aloisi C. Aquaporin-2 (AQP2) urinary excretion and assumption of water with different mineral content in healthy subjects. *Ren Fail.* 2007;29(5):567-72.
59. Buemi M, Senatore M, Gallo GC, Crasci E, Campo S, Sturiale A, Coppolino G, Bolignano D, Frisina N. Pulmonary hypertension and erythropoietin. *Kidney Blood Press Res.* 2007;30(4):248-52.
60. Bolignano D, Coppolino G, Barilla A, Campo S, Criseo M, Tripodo D, Buemi M. Caffeine and the kidney: what evidence right now? *J Ren Nutr.* 2007 Jul;17(4):225-34.
61. Bolignano D, Coppolino G, Campo S, Aloisi C, Nicocia G, Frisina N, Buemi M. Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. *Am J Nephrol.* 2007;27(4):373-8.
62. Bolignano D, Coppolino G, Crasci' E, Aloisi C, Campo S, Sturiale A, Buemi M. Rene e caffeina: un breve gupdateh [A brief "update" on renal effects of caffeina.]. *G Ital Nefrol.* 2007 May-Jun;24(3):188-94.
63. Bolignano D, Coppolino G, Criseo M, Campo S, Romeo A, Buemi M. Aquaretic agents: what's beyond the treatment of hyponatremia? *Curr Pharm Des.* 2007;13(8):865-71.
64. Sturiale A, Coppolino G, Loddo S, Criseo M, Campo S, Crasci E, Bolignano D, Nostro L, Teti D, Buemi M. Effects of haemodialysis on circulating endothelial progenitor cell count. *Blood Purif.* 2007;25(3):242-51.
65. Sturiale A, Campo S, Crasci E, Coppolino G, Bolignano D, Grasso G, Buemi M. Erythropoietin and its lost receptor. *Nephrol Dial Transplant.* 2007 May;22(5):1484-5.
66. Buemi M, Nostro L, Romeo A, Giacobbe MS, Aloisi C, Sturiale A, Bolignano D, Allegra A, Grasso G, Frisina N. From the oxygen to the organ protection: erythropoietin as protagonist in internal medicine. *Cardiovasc Hematol Agents Med Chem.* 2006 Oct;4(4):299-311.

ABSTRACTS IN INTERNATIONAL CONGRESSES

1. Buemi M, Bolignano D, Campo S, Loddo S, Giacobbe MS, Pettinato G, Teti D. Cold pressor test stimulates the mobilization of endothelial progenitor cells in hypertensive and uremic patients. XLIII ERA-EDTA Congress Glasgow, United Kingdom, July 15-18 2006.
2. Buemi M, Tripepi R, Bolignano D, Bitto A, Squadrito F, Spinelli F, Crisafulli A, Coppolino G, Leonardis D, Martorano C, Cambareri F, Tripepi G, Mallamaci F, Zoccali C. Osteoprotegerin and carotid atherosclerosis in dialysis patients : an imaging (eco-doppler) and genic expression study. XLIII ERA-EDTA Congress Glasgow, United Kingdom, July 15-18 2006 ; Twelfth Assisi European meeting on Cardioneurology, March 13-15 2008, Assisi, Italy.
3. Buemi M, Tripepi R, Bolignano D, Bitto A, Squadrito F, Spinelli F, Crisafulli A, Coppolino G, Leonardis D, Martorano C, Cambareri F, Tripepi G, Mallamaci F, Zoccali C. Osteoprotegerin and carotid atherosclerosis in dialysis patients : an imaging (eco-doppler) and genic expression study. Twelfth Assisi European meeting on Cardioneurology, March 13-15 2008, Assisi, Italy.

4. Bolignano D, Coppolino G, Crascì E, Campo S, Bono C, Aloisi C, Nicocia G, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) is correlated with severity of Autosomal Dominant Polycystic Kidney Disease (ADPKD). XLIV ERA-EDTA Congress Barcelona, Spain, June 21-24 2007.
5. Buemi M, Coppolino G, Loddo S, Basile G, Bolignano D, Sturiale A, Teti D. Circulating endothelial progenitor cells mobilization in centenarians : a powerful source for an extended renal life. XLIV ERA-EDTA Congress Barcelona, Spain, June 21-24 2007.
6. Coppolino G, Campo S, Sturiale A, Bolignano D, Giacobbe MS, Buemi M. Endothelial progenitor cells concentration in patients with systemic lupus erythematosus treated with high doses of intravenous immunoglobulins. XLIV ERA-EDTA Congress Barcelona, Spain, June 21-24 2007.
7. Floccari F, Costa C, Coppolino G, Loddo S, Arena A, Bolignano D, Sturiale A, Polito P, Teti D, Buemi M. Genomic damage in endothelial progenitor cells from uremic patients. XLIV ERA-EDTA Congress Barcelona, Spain, June 21-24 2007.
8. Buemi M, Coppolino G, Crascì E, Russo S, Bolignano D, Romeo A. Real time electrocardiogram recording during two different protocols of potassium hemodiafiltration. Preliminary results using a wearable health care system. XLIV ERA-EDTA Congress Barcelona, Spain, June 21-24 2007.
9. Bolignano D, Coppolino G, Campo S, Lacquaniti A, Buemi M. Pathological and Prognostic value of urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) in proteinuric patients with worsening renal function. XLV ERA-EDTA Congress Stockholm, Sweden, May 10-13 2008.
10. Bolignano D, Coppolino G, Medici MA, Sciortino ML, Buemi M. The Aquaretic Agent Satavaptan (SR121463) exerts an anti-proliferative effect on renal cancer: role of vasopressin receptor-2. **BEST ABSTRACT PRESENTED BY YOUNG AUTHORS** XLV ERA-EDTA Congress Stockholm, Sweden, May 10-13 2008.
11. Bolignano D, Coppolino G, Campo S, Bono C, Buemi M. Effect of a single intravenous immunoglobulin infusion (IVIg) on Neutrophil Gelatinase-Associated Lipocalin (NGAL) levels in nephrotic patients with normal renal function. XLV ERA-EDTA Congress Stockholm, Sweden, May 10-13 2008.
12. Coppolino G, Bolignano D, Buemi A, Lacquaniti A, Buemi M. Perioperative prostanoids enhance circulating endothelial progenitor cells mobilization in haemodialysis patients with severe limb ischemia undergoing peripheral revascularization. XLV ERA-EDTA Congress Stockholm, Sweden, May 10-13 2008.
13. Bolignano D, Lacquaniti A, Coppolino G, Campo S, Donato V, Fazio MR, Buemi M. Neutrophil Gelatinase-Associated Lipocalin (NGAL) as an early independent predictor of nephropathy in diabetic patients. World Congress of Nephrology. Milan, May 22-26 2009. 7
14. Bolignano D, Coppolino G, Basile G, Lacquaniti A, Donato V, Fazio MR, Bono C, Buemi M. Neutrophil Gelatinase-Associated Lipocalin (NGAL) predicts cardiovascular mortality in CKD patients affected by chronic heart failure. World Congress of Nephrology. Milan, May 22-26 2009. (Top 20% Abstracts)
15. Bolignano D, Coppolino G, De Paola L, Romeo A, Lombardi L, Buemi M. The Siderophore-binding protein Neutrophil Gelatinase-Associated Lipocalin (NGAL) reflects iron status in hemodialysis patients. World Congress of Nephrology. Milan, May 22-26 2009. (Top 20% Abstracts)
16. Bolignano D, Barresi V, Lacquaniti A, Donato V, Fazio MR, Coppolino G, Barresi G, Buemi M. Neutrophil Gelatinase-Associated Lipocalin (NGAL) correlates with the severity of renal cancer. First Congress of the

Mediterranean Kidney Society. Giardini Naxos, Italy, 2-4 October 2009.

17. Bolignano D, Pettinato G, Lacquaniti A, Coppolino G, Romeo A, Buemi M. Neutrophil Gelatinase-Associated Lipocalin (NGAL) reflects early renal damage in kidney transplant recipients. **BEST ABSTRACT PRESENTED BY YOUNG AUTHORS** XLVII ERA-EDTA Congress Munich, Germany, June 25-28 2010.

18. Bolignano D, Lacquaniti A, Coppolino G, Fazio MR, Donato V, Bono C, Buemi M. Neutrophil Gelatinase-Associated Lipocalin (NGAL) correlates in vivo with the severity of renal cancer. XLVII ERA-EDTA Congress Munich, Germany, June 25-28 2010.

19. Bolignano D, Della Torre A, Lacquaniti A, Costantino G, Fries W, Buemi M. Neutrophil Gelatinase Associated Lipocalin (NGAL) levels in patients with Crohn's disease undergoing treatment with infliximab. XLVII ERA-EDTA Congress Munich, Germany, June 25-28 2010.

20. Bolignano D, Coppolino G, Lombardi L, Buemi M. Neutrophil Gelatinase Associated Lipocalin (NGAL): a new missing link between inflammation and uremic anemia. XLVII ERA-EDTA Congress Munich, Germany, June 25-28 2010.

21. Coppolino G, Bolignano D, De Paola L, Giulino C, Mannella A, Riccio M, Mascaro MA, Fuiano G, Lombardi L, Buemi M. Parathyroid hormone levels and mobilization of circulating bone marrow-derived cells in end-stage renal disease patients. XLVII ERA-EDTA Congress Munich, Germany, June 25-28 2010.

22. De Paola L, Coppolino G, Bolignano D, Buemi M, Lombardi L. PTH variability parameters for identifying high turn-over osteodystrophy disease in hemodialysis patients : an observational retrospective cohort study. XLVII ERA-EDTA Congress Munich, Germany, June 25-28 2010.

23. Bolignano D, Rastelli S, Curatola G, Caridi G, Tripepi R, Tripepi R, Politi R, Catalano F, Delfino D, Ciccarelli M, Mallamaci F, Zoccali C. Ultrafiltration (UF) intensification improves hypertension control in hemodialysis patients but increases arterio-venous fistula complications and cardiovascular events. XLVIII ERA-EDTA Congress Prague, Czech Republic, June 23-26 2011.

24. Bolignano D, Zanolì L, Rastelli S, Marcantoni C, Coppolino G, Lucisano G, Tamburino C, Battaglia E, Castellino P. Increased levels of urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) in coronary artery disease patients reflect the presence of renal artery stenosis. **BEST ABSTRACTS PRESENTED BY YOUNG AUTHORS** XLVIII ERA-EDTA Congress Prague, Czech Republic, June 23-26 2011.

25. Coppolino G, Lucisano G, Presta P, Battaglia E, Pedrelli L, Bolignano D. Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) levels in normoalbuminuric diabetic patients with mild-to-moderate chronic kidney disease. XLVIII ERA-EDTA Congress Prague, Czech Republic, June 23-26 2011.

26. Bolignano D, Zanolì L, Rastelli S, Marcantoni C, Coppolino G, Lucisano G, Battaglia E, Tamburino C, Castellino P. In patients affected by Renal Artery Stenosis (RAS), urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) identifies the presence of impaired renal function. XLVIII ERA-EDTA Congress Prague, Czech Republic, June 23-26 2011.

27. Bolignano D, Zanolì L, Rastelli S, Marcantoni C, Coppolino G, Lucisano G, Tamburino C, Battaglia E, Castellino P. Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) is a strong independent predictor of Atherosclerotic Renovascular Disease (ARVD) in patients with coronary artery disease (CAD). XLVIII ERA-EDTA Congress Prague, Czech Republic, June 23-26 2011.

28. Rastelli S, Zanolì L, Marcantoni C, Bolignano D, Coppolino G, Battaglia E, Tamburino C, Castellino P. In high cardiovascular risk patients the urinary NGAL levels increase according to the number of cardiovascular risk factors. XLVIII ERA-EDTA Congress Prague, Czech Republic, June 23-26 2011.

29. Manfredini F, Bolignano D, Rastelli S, Barillà A, Bertoli S, Ciurlino D, Messa P, Fabrizi F, Zuccalà A, Rapanà R, Fatuzzo P, Rapisarda F, Bonanno G, Lombardi L, De Paola L, Cupisti A, Fuiano G, Lucisano G, Tripepi G, Catizone L, Zoccali C, Mallamaci F. Low intensity, home-based exercise improves physical capacity in dialysis patients: the EXCITE study (EXercise Introduction To Enhance performance in dialysis). Esposto come poster al XLVIII ERA-EDTA Congress, Paris, France, May 24-27 2012.

30. Coppolino G, Comi N, Bolignano D, Piraina V, Talarico R, Colombo A, Lucisano G, Fuiano G. Neutrophil Gelatinase-Associated Lipocalin (NGAL) in glomerulonephritides: an immunohistochemical expression analysis. Esposto come poster al XLVIII ERA-EDTA Congress, Paris, France, May 24-27 2012.